1. Department of Oncology & Metabolism, University of Sheffield, Sheffield, United Kingdom;
2. Southwestern Medical Center and Parkland Health & Hospital System, University of Texas, Dallas, Texas;
3. Novo Nordisk A/S, Søborg, Denmark;
4. ICON plc, London, United Kingdom;
5. ICON plc, San Francisco, USA;
6. ICON plc, Abingdon, United Kingdom;
7. Acaster Lloyd Consulting Ltd, London, United Kingdom